Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis in a patient transplanted from a matched related but non-sibling donor
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e320Keywords:
Acute myeloid leukemia, Matched non-sibling donor, Allogeneic transplantation, Post-transplantation cyclophosphamide, Graft-versus-host diseaseAbstract
While post-transplantation cyclophosphamide (PTCy)-based prophylaxis of graft-versus-host disease (GVHD) was increasingly used not only in haploidentical transplantation but also in transplantation from matched related donors, its benefit in the setting of matched non-sibling donors (MNSD) had not been discussed or reported. A 70-year-old Japanese male who was diagnosed with acute myeloid leukemia with internal-tandem duplication of the FLT3 gene was treated with intensive chemotherapy and quizartinib. After one cycle of consolidation, he was transplanted from an HLA 8/8 matched daughter. GVHD prophylaxis consisted of PTCy, tacrolimus, and mycophenolate mofetil. Neutrophil engraftment was attained at day 16, and he was still in remission at 1 year without complication, but except or grade II acute skin GVHD. Although there had been few reports on PTCy-based GVHD prophylaxis in transplantation from MNSD, our report suggested that these patients could benefit from this type of GVHD prophylaxis.
References
1. Nath K, Zhang MJ, Bye M, Abid MB, Benjamin C, Betts B, et al. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Adv. 2025 Jul 22;9(14):3469-78. https://doi.org/10.1182/bloodadvances.2024014858 DOI: https://doi.org/10.1182/bloodadvances.2024014858
2. Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, et al. Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP/CIBMTR. Transplant Cell Ther. 2025 Dec;31(12):973-88. https://doi.org/10.1016/j.jtct.2025.07.004 DOI: https://doi.org/10.1016/j.jtct.2025.07.004
3. Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023 Jun 22;388(25):2338-48. https://doi.org/10.1056/NEJMoa2215943 DOI: https://doi.org/10.1056/NEJMoa2215943
4. Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin. N Engl J Med. 2025 Jul 17;393(3):243-54. https://doi.org/10.1056/NEJMoa2503189 DOI: https://doi.org/10.1056/NEJMoa2503189
5. Brissot E, Labopin M, Labussiere H, Fossard G, Chevallier P, Guillaume T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024 Feb 19;14(1):31. https://doi.org/10.1038/s41408-024-00990-3 DOI: https://doi.org/10.1038/s41408-024-00990-3
6. Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022 Jun 14;6(11):3378-85. https://doi.org/10.1182/bloodadvances.2021005847 DOI: https://doi.org/10.1182/bloodadvances.2021005847
7. Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 May 13;401(10388):1571-83. https://doi.org/10.1016/S0140-6736(23)00464-6 DOI: https://doi.org/10.1016/S0140-6736(23)00464-6
8. Shen Y, Qi J, Chen J, Xu Y, Chen F, Ma X, et al. Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience. Haematologica. 2021 Nov;106(11):3017-20. https://doi.org/10.3324/haematol.2021.278933 DOI: https://doi.org/10.3324/haematol.2021.278933
9. Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens. 2015 Apr;85(4):252-9. https://doi.org/10.1111/tan.12536 DOI: https://doi.org/10.1111/tan.12536
10. Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood. 2015 Feb 12;125(7):1189-97. https://doi.org/10.1182/blood-2014-10-604785 DOI: https://doi.org/10.1182/blood-2014-10-604785
11. Morishima S, Shiina T, Suzuki S, Ogawa S, Sato-Otsubo A, Kashiwase K, et al. Evolutionary basis of HLA-DPB1 alleles affects acute GVHD in unrelated donor stem cell transplantation. Blood. 2018 Feb 15;131(7):808-17. https://doi.org/10.1182/blood-2017-08-801449 DOI: https://doi.org/10.1182/blood-2017-08-801449
12. Mitsuyoshi T, Arai Y, Kondo T, Kawata T, Hirabayashi S, Tanaka M, et al. HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML. EJHaem. 2025 Feb;6(1):e21088. https://doi.org/10.1002/jha2.1088 DOI: https://doi.org/10.1002/jha2.1088
13. Chorao P, Villalba M, Balaguer-Rosello A, Montoro J, Granados P, Gilabert C, et al. Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide. Transplant Cell Ther. 2025 Mar;31(3):182. e1-182.e11. https://doi.org/10.1016/j.jtct.2024.12.006 DOI: https://doi.org/10.1016/j.jtct.2024.12.006
14. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022 Feb 1;40(4):356-68. https://doi.org/10.1200/JCO.21.02293 DOI: https://doi.org/10.1200/JCO.21.02293
15. Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar;6(3):e132-43. https://doi.org/10.1016/S2352-3026(18)30221-7 DOI: https://doi.org/10.1016/S2352-3026(18)30221-7
16. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-30. https://doi.org/10.1182/blood-2009-11-251595 DOI: https://doi.org/10.1182/blood-2009-11-251595
17. Kanakry CG, O’Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of posttransplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 1;32(31):3497-505. https://doi.org/10.1200/JCO.2013.54.0625 DOI: https://doi.org/10.1200/JCO.2013.54.0625
18. Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, et al. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 May; 102(5):932-40. https://doi.org/10.3324/haematol.2016.152322 DOI: https://doi.org/10.3324/haematol.2016.152322
19. Abedin S, Martens MJ, Bolanos-Meade J, Al Malki MM, Lian Q, Runaas L, et al. Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. Blood Adv. 2025 Jul 22;9(14):3495-501. https://doi.org/10.1182/bloodadvances.2025015964 DOI: https://doi.org/10.1182/bloodadvances.2025015964
20. Korula A, Devasia AJ, Fouzia NA, Nisham PN, Kulkarni U, Lakshmi KM, et al. Outcomes following allogeneic stem cell transplantation using non-sibling family donors. Indian J Hematol Blood Transfus. 2019 Jan;35(1):43-9. https://doi.org/10.1007/s12288-018-0988-z DOI: https://doi.org/10.1007/s12288-018-0988-z
21. Styczynski J, Gil L, Ljungman P, Mikulska M, van der Werf S, Knelange NS, et al. Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematol Pol. 2020;51(2):73-80. https://journals.viamedica.pl/acta_haematologica_polonica/article/view/75189 DOI: https://doi.org/10.2478/ahp-2020-0015
22. Essa MF, Alghazwani S, Abujoub R, Memon S, Alkaiyat M, Ardah H, et al. Comparing between HLAmatched sibling donor allogenic HSCT and non-sibling matched related donor allogenic HSCT outcome in pediatric patients: single center retrospective study. Pediatr Transplant. 2024 Feb;28(1):e14692. https://doi.org/10.1111/petr.14692 DOI: https://doi.org/10.1111/petr.14692
23. Rostami T, Mousavi SA, Kiumarsi A, Kasaeian A, Rad S, Yaghmaie M, et al. Radiation-free reduced-intensity hematopoietic stem cell transplantation with in vivo T-cell depletion from matched related and unrelated donors for Fanconi anemia: prognostic factor analysis. Exp Hematol. 2022 May;109:27-34. https://doi.org/10.1016/j.exphem.2022.02.003 DOI: https://doi.org/10.1016/j.exphem.2022.02.003
24. Aydogdu S, Toret E, Aksoy BA, Aydin MF, Cipe FE, Bozkurt C, et al. Comparison of hematopoietic stem cell transplantation results in patients with beta-thalassemia major from three different graft types. Hemoglobin. 2021 Jan;45(1):25-9. https://doi.org/10.1080/03630269.2021.1872611 DOI: https://doi.org/10.1080/03630269.2021.1872611
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kazutoshi Ebisawa, Takahiro Takeuchi
This work is licensed under a Creative Commons Attribution 4.0 International License.
